VCP
SBIO icon

Verus Capital Partners’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Verus Capital Partners’s Portfolio SBIO Stock Details SBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$55K Sell
1,750
-325
-16% -$12.4K 0.02% 462
2019
Q4 		$88K Buy
+2,075
New +$77K 0.03% 415

Other funds holding SBIO

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
NAM
NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return
CCP
Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

Verus Capital Partners's SBIO Position: Q1 2020 in Review

Verus Capital Partners reduced its ALPS Medical Breakthroughs ETF (SBIO) stake by 16% in Q1 2020, selling an estimated $12.4K and leaving 1,750 shares worth $55K. The position accounts for 0.02% of the portfolio, ranked #462.

Verus Capital Partners first reported a position in SBIO in Q4 2019 and has held it in 2 quarters since. The position peaked at $88K in Q4 2019. 47 funds tracked by Wall St. Rank hold SBIO as of Q1 2020.

  • Verus Capital Partners held 1,750 shares of ALPS Medical Breakthroughs ETF worth $55K as of Q1 2020.
  • Verus Capital Partners sold 325 ALPS Medical Breakthroughs ETF shares in Q1 2020, an estimated $12.4K.
  • ALPS Medical Breakthroughs ETF made up 0.02% of Verus Capital Partners's portfolio in Q1 2020, its #462 holding.
  • Verus Capital Partners first reported a position in ALPS Medical Breakthroughs ETF in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's ALPS Medical Breakthroughs ETF position peaked at $88K in Q4 2019.
  • 47 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.